
## Dawn S Peck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8514050/publications.pdf Version: 2024-02-01



DAWN S DECK

#	Article	IF	CITATIONS
1	Precision newborn screening for lysosomal disorders. Genetics in Medicine, 2018, 20, 847-854.	2.4	99
2	SYT1-associated neurodevelopmental disorder: a case series. Brain, 2018, 141, 2576-2591.	7.6	98
3	Fabry disease in infancy and early childhood: a systematic literature review. Genetics in Medicine, 2015, 17, 323-330.	2.4	82
4	Further delineation of the phenotype resulting fromBRAForMEK1germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 1472-1480.	1.2	79
5	The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. Neurolmage: Clinical, 2013, 3, 539-547.	2.7	42
6	The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease. Genetics in Medicine, 2020, 22, 1108-1118.	2.4	39
7	Disruption of prefrontal function and connectivity in individuals with phenylketonuriaâ~†. Molecular Genetics and Metabolism, 2010, 99, S33-S40.	1.1	32
8	Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. International Journal of Neonatal Screening, 2020, 6, 10.	3.2	32
9	Tractâ€based evaluation of white matter damage in individuals with earlyâ€treated phenylketonuria. Journal of Inherited Metabolic Disease, 2014, 37, 237-243.	3.6	31
10	Morphometric analysis of gray matter integrity in individuals with early-treated phenylketonuria. Molecular Genetics and Metabolism, 2016, 118, 3-8.	1.1	31
11	A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria. Molecular Genetics and Metabolism, 2012, 107, 302-307.	1.1	27
12	Decreased functional brain connectivity in individuals with earlyâ€ŧreated phenylketonuria: evidence from resting state fMRI. Journal of Inherited Metabolic Disease, 2012, 35, 807-816.	3.6	21
13	221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative. Molecular Genetics and Metabolism, 2016, 119, 75-82.	1.1	18
14	Response to immunotherapy in a patient with adult onset Leigh syndrome and T9176C mtDNA mutation. Molecular Genetics and Metabolism Reports, 2016, 8, 28-32.	1,1	14
15	Multiplex testing for the screening of lysosomal storage disease in urine: Sulfatides and glycosaminoglycan profiles in 40 cases of sulfatiduria. Molecular Genetics and Metabolism, 2020, 129, 106-110.	1.1	10
16	DNA Carrier Testing and Newborn Screening for Maple Syrup Urine Disease in Old Order Mennonite Communities. Genetic Testing and Molecular Biomarkers, 2010, 14, 205-208.	0.7	9
17	Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease. International Journal of Cardiology, 2019, 292, 91-94.	1.7	8
18	Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease. Mayo Clinic Proceedings, 2019, 94, 84-88.	3.0	8

DAWN S PECK

#	Article	IF	CITATIONS
19	Detecting 3D Corpus Callosum abnormalities in phenylketonuria. International Journal of Computational Biology and Drug Design, 2009, 2, 289.	0.3	7
20	The effects of early-treated phenylketonuria on volumetric measures of the cerebellum. Molecular Genetics and Metabolism Reports, 2020, 25, 100647.	1.1	7
21	Tracking clinical genetic services for newborns identified through newborn dried bloodspot screening in the United States—lessons learned. Journal of Community Genetics, 2011, 2, 191-200.	1.2	5
22	Shape analysis of corpus callosum in phenylketonuria using a new 3D correspondence algorithm. Proceedings of SPIE, 2010, , .	0.8	1
23	Response to letter to the editor: Why does Leigh syndrome responds to immunotherapy?. Molecular Genetics and Metabolism Reports, 2016, 8, 85-86.	1.1	1